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Ankylosing spondylitis (AS): form of arthritis characterized by
chronic inflammation of the axial skeletal system that causes
back pain and loss of mobility with strong potential for slow,
eventual spinal fusion1
• Affects 0.2-0.5% of the United States population
• No known cure, yet greater than 60 genetic components are
involved1
HLA-B27: genetic component highly correlated with AS.
Presence creates inflammatory response at bony attachment
sites of tendons, ligaments, and joint capsules.2
Presentation can vary widely and may include:
• Intermittent and/or significant back pain and stiffness across
multiple body segments for long periods of time3
• Peripheral joint involvement
• Chronic inflammatory-related comorbidities4
Purpose: Describe a comprehensive approach for physical
therapy (PT) management of AS to assist clinical decision
reasoning and clinical decision making and enhance care
management in this patient population.
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Hallmark feature of AS: sacroiliac (SI) joint involvement3,5

Patient Presentation

• 27-year old female patient services representative referred to
outpatient therapy
• MRI confirmed medical diagnosis of AS
• Limited active range of motion (AROM): thoraco-lumbar flexion
and extension, lumbar lateral flexion and rotation (pain with all)
• Limited strength: hip (all planes, pain), plantarflexors
• Neural assessment: parasthesia to left foot, occasionally to
right knee
• Activities of daily living: independent, modified or limited
activity when pain significantly increased
• Relieving factors: minimal relief with shifting positions,
prescribed medication
• Goals: long term preservation of independent functional
mobility, return to recreational activities, minimize need for
pain medication
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Legend: a: AROM – active range of motion, b: cm – centimeters, c: WNL – within normal limits,
d: SB – sidebend, e: SLR – straight leg raise, (*) denotes pain

Discussion
• Greatest improvement reported after initiation of Cosentyx and
Remicade, immunosuppressant drugs utilized to decrease
systemic inflammation7,8
• Soft tissue mobilization combined with interferential current
therapy seemed to provide greatest pain relief during PT
• Goals seemed to provide little insight quantifying patient
progress and condition
Limitations: limited evidence available regarding PT
management of AS, publication of this case report prior to
patient discharge from PT
Future research opportunities: clinical practice guideline,
treatment guidelines for active vs. non-active AS
Take home point: This case demonstrated the evolving and
ever-changing nature of AS. Collaborative care, pharmaceutical
intervention, and patient-centered, symptom-focused
intervention seemed to provide greatest benefit for this patient.
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